



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/826,379	04/19/2004	Masaaki Nomura	159-84	9722
23117	7590	05/11/2007	[REDACTED]	EXAMINER
NIXON & VANDERHYE, PC 901 NORTH GLEBE ROAD, 11TH FLOOR ARLINGTON, VA 22203			MAEWALL, SNIGDHA	
[REDACTED]	[REDACTED]	[REDACTED]	ART UNIT	PAPER NUMBER
[REDACTED]	[REDACTED]	[REDACTED]	1615	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	MAIL DATE	DELIVERY MODE
[REDACTED]	[REDACTED]	[REDACTED]	05/11/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)
	10/826,379	NOMURA ET AL.
	Examiner	Art Unit
	Snigdha Maewall	1615

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on ____.
 2a) This action is FINAL. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-5 and 8-11 is/are pending in the application.
 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
 5) Claim(s) ____ is/are allowed.
 6) Claim(s) 1-5 and 8-11 is/are rejected.
 7) Claim(s) ____ is/are objected to.
 8) Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on ____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. ____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date. ____ .
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)	5) <input type="checkbox"/> Notice of Informal Patent Application
Paper No(s)/Mail Date <u>04/19/04</u> .	6) <input type="checkbox"/> Other: ____ .

DETAILED ACTION

Summary

1. Receipt of Preliminary Amendment, Applicants Arguments/Remarks, Foreign Priority and IDS filed on 04/19/2004 is acknowledged.
Claims 1-5 and 8-11 are pending in this application and claims 1-5 and 8-11 will be prosecuted on the merits.

Claim Rejections - 35 USC § 102

2. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

3. Claims 1-3, 5, 8 and 9 are rejected under 35 U.S.C. 102(b) as being anticipated by (US Patent 5,354,748) to Sugita et al.

Sugita et al. discloses oral antibacterial compositions containing a penem or carbapenem antibiotic (abstract). Sugita et al. teaches that the antibacterial compositions of their invention can be formulated for oral use such as tablets, granules, powders, syrups, or liquid preparations. Sugita et al. also teaches that pharmaceutical carriers which are known in the art can be used. These carriers include sucrose (column

5, lines 52-65). Examples 11, 14 and 17 each teach dry syrup containing a penem compound, sucrose, mannitol, and other known excipients. The sucrose is present at 56% and the mannitol is present at 31% in example 11.

Claim Rejections - 35 USC § 103

4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

5. Claims 4, 10 and 11 are rejected under 35 U.S.C. 103(a) as being unpatentable over (US Patent 5,354,748) to Sugita et al.

Sugita et al. are discussed above as teaching oral formulations for the administration of a penem compound, wherein the formulation comprises sucrose and mannitol. Sugita et al. does not specifically teach that the penem compound be faropenem sodium, or that the mannitol be in the form of D-mannitol. However, it is the position of the examiner that these limitations do not render patentable distinction to the instant claims. One skilled in the art would have been motivated to use any well known penem antibiotic in the teachings of Sugita et al., particularly because the reference refers to penem and carbapenem antibiotics in general. Additionally, it is the position of the examiner that Sugita et al. teach the use of mannitol in general, and this teaching is generic to the particular type of mannitol claimed by Applicant. Furthermore, absent a showing of unexpected results, the choosing of a specific mannitol when given a

Art Unit: 1615

teaching to mannitol in general would be routinely done by one of ordinary skill in the art. Any showing of unexpected results with regard to the particular active or the particular excipient must be based solely on the particular limitation. Therefore, this invention as a whole would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made.

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Snigdha Maewall whose telephone number is (571)-272-6197. The examiner can normally be reached on Monday to Friday; 8:30 a.m. to 5:00 p.m. EST. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Woodward can be reached on (571) 272-8373. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Snigdha Maewall

Art Unit 1615


Goillamudi S. Kishore, PhD
Primary Examiner
Group 1600